Zions Bancorporation N.A. Purchases 4,626 Shares of Repligen Co. (NASDAQ:RGEN)

Zions Bancorporation N.A. grew its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 48.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,079 shares of the biotechnology company’s stock after buying an additional 4,626 shares during the quarter. Zions Bancorporation N.A.’s holdings in Repligen were worth $2,027,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of RGEN. Segall Bryant & Hamill LLC bought a new stake in Repligen during the fourth quarter worth about $19,021,000. Vanguard Group Inc. increased its position in shares of Repligen by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock worth $734,251,000 after purchasing an additional 56,723 shares during the last quarter. LPL Financial LLC raised its stake in shares of Repligen by 47.6% during the 4th quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company’s stock worth $4,873,000 after purchasing an additional 10,395 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Repligen in the 4th quarter valued at approximately $667,000. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Repligen in the fourth quarter valued at $1,555,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on the stock. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Royal Bank of Canada raised their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. Evercore ISI began coverage on Repligen in a research report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective for the company. Finally, Canaccord Genuity Group lifted their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $178.64.

Repligen Stock Performance

RGEN opened at $141.95 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a market capitalization of $7.97 billion, a PE ratio of -278.33, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The business has a fifty day simple moving average of $155.62 and a 200 day simple moving average of $148.36. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $187.25.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Research analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Insiders Place Their Bets

In related news, Director Margaret Pax purchased 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This represents a 31.53 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.